Purpose: The clinical effects of sunitinib on human myeloidderived suppressor cell (MDSC) subsets and correlation of the T-cell-mediated immune responses and clinical outcomes in patients with oligometastases treated by stereotactic body radiotherapy (SBRT) have been evaluated.
Introduction
Stereotactic body radiotherapy (SBRT) utilizes high doses of focused radiation which selectively spares adjacent healthy organs to safely ablate various primary and metastatic tumors (1). Patients with limited distant metastases or oligometastases, which were historically considered incurable, present a particularly attractive patient population for applying SBRT (2) . Although SBRT for oligometastases can successfully control the majority of targeted tumors, the majority of patients eventually develop additional distant metastases.
Adding systemic therapy to radiation therapy has improved overall survival (OS) in various solid tumor types by enhancing locoregional control of the targeted tumors and by preventing distant metastases (3) . Agents that enhance the response to radiation include cytotoxic chemotherapeutic agents and biologically targeted agents, such as EGFR inhibitors, immunotherapies, and angiogenesis inhibitors (4) . Identification of an optimal reagent for enhancing systemic antitumor responses will significantly benefit SBRT therapy.
Sunitinib (Sutent), a multitargeted tyrosine kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, c-kit, FLT3, and RET, is a well-studied angiogenesis inhibitor with an acceptable singleagent toxicity profile (5) . Preclinical studies suggest that sunitinib and other angiogenesis inhibitors may enhance the antitumor responses of radiotherapy (6) . Therefore, we initiated a phase I/II clinical trial to evaluate the safety and efficacy of concurrent sunitinib and SBRT for patients with oligometastases (7) . Recently, we reported that the 4-year progression-free survival (PFS) and OS rates of patients with historically incurable oligometastases in this phase I/II clinical trial were 34% and 29%, respectively (8) .
Our data suggest that sunitinib treatment during radiotherapy may have a significant effect on micrometastases, thus preventing distant progression in a subset of patients with oligometastases (9) . Several research groups, including ours, have demonstrated the robust effects of sunitinib on reducing myeloid-derived suppressor cells (MDSC; refs. 10, 11). However, correlation of this effect on MDSC with T-cell responses and clinical outcomes in SBRT patients has not been previously explored.
In humans, myeloid cell markers CD33, CD11b, and HLA-DR are used to characterize human MDSC and CD15 is specific for granulocytic MDSC. However, the absence of a universal marker makes proper identification of human monocytic MDSC more difficult and complicated. There are two monocytic populations in human blood that can be distinguished by the lipopolysaccharide coreceptor, CD14, and Fcg-receptor, CD16. In healthy individuals, CD14 þþ
CD16
À classical monocytes are the major population ($90%), whereas CD14 þ CD16 þ nonclassical monocytes (proinflammatory monocytes) account for only 5% to 10% of circulating monocytes. Nevertheless, these proinflammatory monocytes (CD14 þ CD16 þ ) are significantly increased in patients with systemic infections (12) , and are associated with cardiovascular disease and atherosclerosis (13) . In addition, it has been reported that CD14 þ
þ proinflammatory monocytes selectively upregulate Tie2 expression and may be involved in tumor infiltration and angiogenesis (14) , and have biologic activities similar to M2-like macrophages. Recently, our group demonstrated that monocytic MDSC could further differentiate into an immunosuppressive M2 phenotype or a proinflammatory M1 phenotype dependent on the internal signaling of mouse PIRB or its human counterpart, LILRBs (leukocyte immunoglobulin-like receptors B; refs. 15, 16) . In the tumor microenvironment, MDSC with the M2-like phenotype are dominant and produce large amounts of IL-10 and arginase, induce anergy of antitumor immune cells, and expand immunosuppressive regulatory T cells (Treg). Furthermore, promoting MDSC differentiation into the M1 phenotype has been hypothesized as an attractive strategy for preventing tumor growth and angiogenesis (15, 16 
Materials and Methods
Patient eligibility for phase I/II clinical trial Between February 2007 and September 2010, 46 patients were enrolled in a phase I or II single institution clinical trial using sunitinib and SBRT to treat limited oligometastatic diseases. Details about clinical trial eligibility were described previously (7) . Briefly, eligible patients had 1 to 5 sites of active metastatic disease measuring 6 cm based on whole body imaging (PET or CT scans of chest, abdomen and pelvis). Patients were treated with sunitinib or SBRT following established guidelines (see Drug administration and radiation guidelines). Among the patients enrolled in this clinical trial, the peripheral blood of 19 patients was collected and banked for immune studies at the indicated time points. Not all time points were collected for certain patients due to disease progression.
Patient clinical outcomes were defined as follows: PFS is the length of time after treatment that a patient lives with no evidence of disease progression; CSS is the length of time from the start of treatment to the date of death from disease; OS is the length of time from the start of treatment to the date of death from any cause.
Nineteen pretreatment cancer patients with different types of cancers at the same tumor stage were recruited (Supplementary Table S1 ). All of the cancer patients had biopsy-confirmed diagnosis of a solid malignancy. On the basis of the extent of the decrease in the CD33 ]. Defining sunitinibresponders or sunitinib-nonresponders according to T-cell classification was based on increased or decreased Tbetþ expression in CD4 T cells after sunitinib treatment, respectively. Twenty-one healthy donor samples were obtained from various sources including blood bank samples and healthy volunteers without a known diagnosis of malignancy. A control cohort receiving radiation therapy alone was recruited from Mount Sinai Medical Center (New York, NY; n ¼ 5) and the University of Pittsburgh Medical Center (Pittsburgh, PA; n ¼ 4). This study was approved by both Institutional Review Boards and was conducted in accordance with federal and institutional guidelines.
Drug administration and radiation guidelines
The dose administration and radiation guidelines for the patients in this study were described previously (8) . Sunitinib was administered orally once daily (37.5 mg) in 6-week cycles consisting of 4 weeks of treatment followed by 2 weeks without
Translational Relevance
In the present study, we have identified human CD33 Peripheral blood mononuclear cell isolation Peripheral blood (20 mL) was drawn from trial patients before sunitinib treatment (time point A), after 7 days of sunitinib treatment before SBRT (time point B), and after SBRT for 6 to 30 days (time point C). Peripheral blood was drawn into heparincontaining tubes. Peripheral blood mononuclear cells (PBMC) were purified and isolated within 2 hours of blood collection utilizing Ficoll-Paque PLUS (GE Healthcare), and stored in liquid nitrogen for subsequent analysis.
Determination of patient T-cell responses and MDSC suppression assay
Patient PBMC samples were stimulated with anti-CD3/CD28 (1 mg/mL) for 72 hours. To assay cellular proliferation, tritiated thymidine was added during the last 8 hours, and proliferative activity levels were determined using a beta counter, and presented as counts per minute (CPM). For the MDSC suppression assay, sorted cell populations were cocultured with T cells at 1:1, 0.5:1, 0.25:1, 0.125:1 ratios in the presence of anti-CD3/anti-CD28 (1 mg/ mL) for 72 hours. Suppression index was calculated as (1 À (CPM of T cells cocultured with MDSCs/CPM of T cells alone)) Â 100%.
Statistical analysis
Student t test was used to compare MDSC subsets from cancer patients and healthy donors. Paired t test was used to compare results from the same patient at the different time points (A, B, and C). The Log-rank test was used to compare the survival benefit between sunitinib responders and nonresponders. All statistical tests were one-tailed and all analyses were conducted using Prism and SPSS.
Results
Significantly more granulocytic MDSC and CD33 ; P < 0.01, Fig. 1B ). On the other hand, the frequency of classical monocytic cells (CD14 þ CD16 À ) varied and showed no significant differences between cancer patients and healthy donors.
Sunitinib induces apoptosis of mouse M2-like monocytic MDSC and decreases the suppressive activity of human CD33
To characterize the immunomodulatory effect of sunitinib on MDSC, we treated human PBMC with sunitinib for 48 hours in vitro and found that sunitinib treatment sharply decreased the CD33 þ
CD14
þ CD16 þ population and increased apoptotic Fig. 2A and B). Interestingly, these apoptotic cells had higher CD206 expression, which is Fig. S5B ). The findings support our hypothesis that sunitinib treatment led to preferential apoptosis of the M2 but not M1 subset. Moreover,
monocytes from cancer patients resulted in significantly decreased levels of phosphorylated-STAT3, CD206, and arginase I, but significantly higher levels of iNOS, similar to the immunophenotype of M1-like cells. This population did not appear to arise from differentiation into classical macrophages, as the frequency of CD169 þ cells was not significantly different between these two populations (data not shown). We also found that sorted CD33 
from cancer patients before and after sunitinib treatment.
À cells and the suppressive activity was significantly decreased by sunitinib treatment (Fig. 2D) and inhibited by arginase inhibitor (Supplementary Fig. S5D ). Similar to our findings, several studies reported that arginase inhibitor could significantly decrease the immunosuppressive activity of human myeloid suppressor cells against T-cell proliferation (17, 18) . However, we cannot rule out the possibility 
MDSCs
Given the effects observed with in vitro sunitinib treatment, we explored the in vivo effect by comparing PBMC from patients receiving sunitinib and SBRT with those from control patients receiving radiation therapy alone. In patients treated with sunitinib, when time point A (before taking sunitinib) was 
Chen et al. 3A and B and Supplementary Fig. S1A and S1B). When gating on the CD33 þ population, human mono- and D and Supplementary Fig. S1C and S1D ). Comparing time point A and time point C (sunitinib þ SBRT), CD33 þ HLA-DR
were significantly decreased (Fig. 3B-D ). There were no significant differences in the CD33
cytes in patients who received radiation alone (Fig. 3E) . Interestingly, sunitinib treatment substantially decreased arginase þ and (Fig. 3F) . The percentage changes in specific cell populations are presented in Supplementary Fig. S1 . These results indicate that sunitinib treatment significantly decreased various MDSC populations while radiotherapy alone did not appear to significantly affect MDSC populations. Supplementary Fig. S1C ). On the other hand, CD33 (Fig. 3D) and phosphorylated STAT3 þ cells (Fig. 3F ) in this population were significantly decreased in the R group (P ¼ 0.0443 and 0.0050, respectively). There is a significant reduction in CD33
Significant reductions in CD33
À MDSC (before sunitinib treatment vs. sunitinib þ SBRT, and sunitinib treatment alone vs. sunitinib þ SBRT) in total and NR group (Fig. 3B and D) . In addition to STAT3 phosphorylation, we also observed that phos-
À monocytes were noticeably downregulated in the R group, but not the NR group (Supplementary Fig. S2 ). In our previous study, we found that sunitinib skewed a tolerogenic tumor microenvironment by reducing the Treg and MDSC populations in tumor-bearing mice (10) . In this study, we also observed that sunitinib induced a favorable phenotypic switch of human monocytic MDSC to M1-like macrophages, which may also contribute to the observed loss of Treg activation (10) . It has been suggested that Treg (regulatory T cells) and Breg (regulatory B cells) are important immunosuppressive cell types in cancer patients. Therefore, we also determined the profiles of CD4
this study. The results indicate that there are no substantial changes in these parameters pre-and post-sunitinib treatment, but there is a marked decrease in Treg (P ¼ 0.0138) in all cancer patients treated with sunitinib before and after SBRT (Fig. 4A) . However, interestingly, after we stratified the patients into sunitinib-responsive and nonresponsive groups by the extent of the reduction in CD33 þ CD11b þ MDSC, we found that sunitinib-responders showed a significant decrease in Treg cell population post-sunitinib treatment and further reduction in post sunitinib þ SBRT treatment (Fig. 4A ). In contrast with the above findings, sunitinib-nonresponders exhibited less effects on Treg post-sunitinib treatment (Fig. 4A ) and sunitinib þ SBRT treatment (Supplementary Fig. S1E ). This suggests that SBRT may potentially synergize the immunemodulatory effect of sunitinib on Treg suppression in sunitinib-responders, but not in sunitinib-nonresponders. Moreover, these results may suggest that there is a high correlation between reductions in CD33
þ MDSC and Treg populations, which were found to be beneficial responses from sunitinib treatment. The combination of sunitinib and SBRT also considerably decreased the CD19/CD5 double positive B cells in all patients (both sunitinib-responders and sunitinibnonresponders; Fig. 4B ).
Sunitinib treatment promotes the development of IFNgproducing effector T cells in clinical responders
We hypothesized that patients who undergo treatment with sunitinib and SBRT would likely also have changes in effector Tcell function. To investigate this possibility, we analyzed the expression of Tbet (T-box expressed in T cells), a key transcriptional factor that initiates the transcription of IFNg in both CD4 and CD8 effector T cells. We found a significant increase in the expression of Tbet, but not RORgt, a key factor driving development of Th17 (data not shown), in both CD4 þ and CD8 þ T cells present in patient PBMC following concurrent sunitinib and radiotherapy (Fig. 4C) . We analyzed the proliferative activity of T cells isolated from trial patients resulting from in vitro CD3/CD28 stimulation for 72 hours. The results showed that sunitinib significantly increased the proliferative activity of T cells in all patients (Fig. 4D , A to B, P ¼ 0.0384). Furthermore, we did not observe significant changes in Treg, B cells, CD4, or CD8 Tbet þ cells or any increases in T-cell proliferation in PBMC from patients treated with radiation therapy alone (Fig. 4E) . The results suggest that the increases in Tbet expression and proliferative activity of T cells can be attributed to sunitinib-mediated immune-modulatory activity.
Correlation between immune responses and clinical outcomes based on changes in CD33
In our previous study, we found that sunitinib treatment increased the production of the Th1 cytokine IFNg (10), which is driven by the key transcriptional factor Tbet. Therefore, we further stratified the 19 trial patients into responders (n ¼ 10) and nonresponders (n ¼ 9) based on increases or decreases in the percentage of Tbet þ cells in CD4 þ T cells following sunitinib treatment (see Materials and Methods). Similar to the CD33 þ CD11b þ myeloid cell-based classification, we found significant Fig. S4A and S4B) . Furthermore, Fig. S4B ). The proliferative activity of T cells was also substantially increased after sunitinib treatment in responders ( Supplementary Fig. S4C ). On the basis of the Tbet þ T-cell-based classification, there was a moderate reduction in Treg numbers after SBRT in responders (P ¼ 0.0281) and in nonresponders (P ¼ 0.0417), but no significant changes were detected when comparing the before and after sunitinib treatment time points (Supplementary Fig. S4D) . We further evaluated whether the effects of 7-day sunitinib treatment on MDSC or T cells could be used as an immune endpoint that would predict clinical outcomes. We correlated the myeloid cell-or T-cell-based classifications of responses to sunitinib treatment with clinical outcomes. When we analyzed the survival across all patients, there were no significant differences in PFS, CSS, or OS between sunitinib-responsive and nonresponsive groups based on the two different classifications (Fig. 5) . This could be due to the limited sample sizes. Of note, somewhat surprisingly, patients who were considered responders based on T-cell criteria might exhibit worse PFS, CSS, and OS at an early phase in the trial (less than 500 days). In contrast, responders based on myeloid cell criteria tended to show improved PFS and CSS outcomes compared with nonresponders. The results from these analyses suggest that the myeloid cell-based classification may be more useful for prognosis, as it more effectively predicts those who are likely to benefit from sunitinib treatment clinically. However, further investigation incorporating longer follow-up periods and greater patient numbers may be required to draw significant conclusions.
Discussion
Previous studies using an animal model (19) and human tumor cell lines (20) have demonstrated the synergistic antitumor effects of sunitinib and SBRT (21) , but the underlying mechanisms remain unclear. In a preclinical evaluation of sunitinib as a radiosensitizer for human prostate cancer, Brooks and colleagues concluded that sunitinib and radiation therapy do not interact directly to radiosensitize PC3 tumor cells in vivo (22) . However, the fact that there was additional delay in tumor growth suggested that sunitinib may be acting on the tumor stroma by suppressing its ability to sustain regrowth from the irradiated tumor. In our previous study, we demonstrated that sunitinib modulated the function and numbers of MDSC and Treg in the tumor microenvironment and promoted antitumor immune responses (10) . In our clinical trial, we established that sunitinib could be an immune modulator in patients receiving the combination of sunitinib treatment and SBRT. The mechanism we propose can also explain the results from previous studies where sunitinib was combined with SBRT.
The presence and frequency of circulating and infiltrating MDSC have been correlated with the promotion of angiogenesis, clinical cancer staging, and metastatic status (23, 24) , thus providing a potential new target for treating cancer. However, a universal marker for human MDSC, particularly monocytic MDSC, has not been identified. Human monocytes can be classified into two subsets based on CD14 and CD16 expression levels: intermediate
þþ (25, 26) .
þ human monocytes have been reported to be proinflammatory monocytes (27) and are highly associated with various human diseases, including acute liver failure (28) , generalized pustular psoriasis (29) , chronic hepatitis B (30), inflammation and microbial infections (31) . In this study, we found the CD33 þ
CD14
þ CD16 þ population to be significantly augmented in cancer patients with high phosphorylated-STAT3 and arginase expression levels and elevated immune-suppressive activity, which lead us to identify them as human monocytic MDSC. Most importantly, sunitinib treatment effectively decreased the frequency and suppressive activity of CD33
The variability of clinical outcomes in response to treatment with tyrosine kinase inhibitors may be due to a variety of biologic parameters including FLT3-internal tandem duplication mutations (32), polymorphisms (33) , and miRNA expression signature (34) . It is known that some tumor-derived factors, including Bv8, SDF-1a, G-CSF, can stimulate myelopoiesis, initiate and expand myeloid cell mobilization to circulating blood (35) (15, 16) . Sunitinib, a multitargeted tyrosine kinase inhibitor, has the potential to drive MDSC toward the M1 phenotype via multiple mechanisms. Sunitinib-mediated inhibition of STAT3 phosphorylation could be the underlying mechanism on myeloid cell survival (39) and MDSC-suppressive function (40) , as well as arginase expression (17) . On the other hand, phosphorylation of STAT1 plays an important role in macrophage activation, monocyte differentiation, and proinflammatory cytokine/chemokine production via IFNg (41), IL-27 (42), or IL-10 signaling cascades (43) . In this study, we found that phosphorylation of STAT1
À cells after sunitinib treatment in total patients and the Responder group ( Supplementary Fig. S2 ). This suggests that sunitinib may hamper the inflammatory status of individuals by suppressing differentiation of inflammatory monocytes, characterized as the CD33
þ population, or secretion of proinflammatory cytokines in human monocytes. Therefore, sunitinib may magnify the radiotherapy-induced cytotoxic effect on immunosuppressive cells, and modulate myeloid differentiation into M1 versus M2 functional phenotypes. In addition, it has been reported that the ionizing radiation, as an immunologic adjuvant, can increase damage-associated molecular patterns emitted from dying tumor cells with high immunogenicity, including calreticulin, high-mobility group box 1 protein, and ATP (44, 45) . This radiotherapy-induced immunogenic tumor cell death can potentially synergize with the antitumor and M1-polarizing effects of sunitinib. This study was conducted through the use of a limited cohort of heterogenous patients with one to five radiographically apparent distant metastases. The cancer types included lung carcinoma, head and neck squamous cell carcinoma, prostate adenocarcinoma, hepatocellular carcinoma, colorectal adenocarcinoma, renal cell carcinoma, melanoma, thyroid carcinoma, and salivary gland carcinoma (Supplementary Table S1 ). The diverse carcinoma types of recruited patients enabled us to demonstrate the beneficial effects of sunitinib treatment in combination with SBRT for multiple cancer types. In contrast, most previous sunitinib clinical trials were focused on a single cancer type. In a previous study, Ko and colleagues (46) found that sunitinib-based therapy had the potential to modulate antitumor immunity by reversing MDSC-mediated immunosuppression in renal cell carcinoma patients. The novelty of this study is the correlation of the immunemodulation effects of sunitinib and radiation therapy and the frequencies of MDSC in responders versus nonresponders with survival prognosis of multiple cancer types. A (52) reported that a trastuzumab-docetaxel-based treatment, but not an anthracyclines-based regimen, could induce a significant T-bet induction in peritumoral lymphoid tissues that predicts a better survival prognosis in breast cancer patients. These findings suggest that the induction of Tbet þ T cells varies, depending on the treatments. Importantly, a single factor, Tbet in T cells, may not be sufficient to predict cancer prognosis of patients. In this study, we observed that sunitinib treatment alone did not significantly induce Tbet in CD4 or CD8 T cells of the entire cohort of cancer patients in the trial (Fig. 4C) The presence of Tbet þ CD4 or CD8 T cells in peripheral blood did not by itself lead to a clinical benefit in cancer patients treated with sunitinib. These findings strongly suggest that the immunologic effect of sunitinib may be predominantly mediated through modulation of myeloid cells. However, more factors may need to be included to address the roles of various T-cell subsets, Th1 and Tc, in the prognosis of cancer patients treated with sunitinib only (51) . Taken together, CD33 Although a relatively small population of patients was investigated in this study, the sunitinib-responders, which had greater sunitinib-related reductions in the frequency of MDSC, tended to exhibit improvement in PFS and CSS. This reduction in MDSC frequency was not observed in patients treated with SBRT alone. This suggests that classifying immune responsiveness of patients based on reductions in MDSC frequency could potentially be used by physicians to predict the likelihood that an individual patient would benefit from sunitinib treatment in combination with radiation therapy. Similar to our findings, Meyer and colleagues suggested that the low frequency of Lin À
þ HLA-DR À monocytic MDSC might be used as a predictive biomarker of patient response to ipilimumab treatment (53) . This is the first study to investigate the therapeutic and immunologic effects of concurrent sunitinib and SBRT on various immunologic parameters, including human granulocytic MDSC and different subsets of monocytic MDSC, T cells, and B cells in patients with oligometastases and to correlate the different measurements with clinical outcome. In conclusion, concurrent therapy using the multitargeted tyrosine kinase inhibitor sunitinib and SBRT in patients with oligometastases has the potential to modulate antitumor immunity by reversing MDSC-mediated tumor-induced immune suppression, which may be beneficial to cancer immunotherapies.
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